Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/01/16/2809755/0/en/Emergex-Announces-R-D-Collaboration-with-DEKA-Research-Development-Corp-for-Assessment-of-Emergex-s-Immunotherapeutic-Candidates-with-DEKA-s-Intradermal-Therapeutic-Applicator.html
https://www.globenewswire.com//news-release/2023/12/18/2797690/0/en/Successful-Transfer-of-New-Drug-Application-NDA-Acknowledged-by-U-S-FDA-from-Former-Zosano-Pharma-to-Emergex-for-Investigational-Microneedle-Based-Drug-Delivery-Patch.html
https://www.globenewswire.com//news-release/2023/11/17/2782493/0/en/Emergex-Signs-Contract-of-1-79M-with-the-UK-Department-of-Health-and-Social-Care-s-UK-Vaccine-Network-UKVN-to-Advance-Its-Novel-Synthetic-T-Cell-Priming-Set-Point-Candidate-Against.html
https://www.globenewswire.com//news-release/2023/10/05/2755225/0/en/Emergex-and-Saudi-Arabia-s-Vaccine-Industrial-Company-VIC-have-Signed-MoU-to-Advance-First-of-its-Kind-Infectious-Disease-Solutions.html
https://www.globenewswire.com/news-release/2023/07/19/2707229/0/en/Emergex-Reports-Promising-Data-from-Completed-Swiss-Phase-I-Trial-of-CoronaTcP-T-Cell-Priming-Immune-Set-Point-Candidate-for-Betacoronaviruses.html
https://www.globenewswire.com//news-release/2022/11/28/2562991/0/en/Emergex-Generates-Chikungunya-Ligandome-a-Milestone-in-the-Development-of-its-T-cell-Adaptive-Vaccine.html
https://www.fiercepharma.com/pharma/bankrupt-zosano-sells-intradermal-delivery-tech-emergex-vaccines
https://www.globenewswire.com/news-release/2022/10/12/2532712/0/en/Emergex-Acquires-Intradermal-and-Patch-Drug-Delivery-Technology-with-Its-Manufacturing-Equipment-from-Zosano-Pharma.html
https://www.globenewswire.com/news-release/2022/07/28/2487492/0/en/Emergex-Announces-GMP-Production-of-its-CD8-T-cell-Universal-Influenza-Vaccine.html
https://www.globenewswire.com/news-release/2022/07/01/2472615/0/en/Emergex-Vaccines-signs-Heads-of-Terms-for-a-Collaboration-with-Molecular-Biology-Institute-of-Paran%C3%A1-IBMP-in-Brazil.html